Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)

DSpace Repository

Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)

Author: Arendt, A. -M.; Heubach, F.; Maier, C. P.; Giardino, S.; Jung, G.; Kowalewski, E.; Rabsteyn, A.; Amorelli, G.; Seitz, C.; Schlegel, P.; Handgretinger, R.; Lang, P.
Tübinger Autor(en):
Arendt, Anne-Marie
Heubach, Florian
Maier, Claus-Philipp
Jung, Gundram
Kowalewski, E.
Rabsteyn, Armin
Amorelli, Germano
Seitz, Christian
Schlegel, Paul Martin
Handgretinger, Rupert
Lang, Peter
Published in: Cancer Immunology Immunotherapy (2023), Bd. 72, H. 11, S. 3813-3824
Verlagsangabe: New York : Springer
Language: English
Full text: http://dx.doi.org/10.1007/s00262-023-03536-x
ISSN: 0340-7004
DDC Classifikation: 610 - Medicine and health
570 - Life sciences; biology
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)